Functional connections and pathways of coenzyme Q10-inducible genes: An in-silico study

IUBMB Life

Volumn 59, Issue 10, 2007, Pages 628-633

  Döring, Frank ^a   Schmelzer, Constance ^a   Lindner, Inka ^a   Vock, Christina ^a   Fujii, Kenji ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b KANEKA CORPORATION   (Japan)

Author keywords

Cardiovascular diseases; Coenzyme Q10; In silico analysis

Indexed keywords

BETA ARRESTIN; C REACTIVE PROTEIN; CLOX PROTEIN; EVI1 PROTEIN; G PROTEIN COUPLED RECEPTOR; HOXC PROTEIN; HOXF PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; INTERLEUKIN 5; JANUS KINASE; KANEKAQ10; STAT PROTEIN; THROMBIN; TRANSCRIPTION FACTOR; UBIDECARENONE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ARTICLE; BINDING SITE; COMPUTER MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG MECHANISM; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; NUCLEOTIDE SEQUENCE; PROMOTER REGION;

CACO-2 CELLS; COENZYMES; COMPUTATIONAL BIOLOGY; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; SIGNAL TRANSDUCTION; SOFTWARE; UBIQUINONE;

ANIMALIA;

EID: 34648828494     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1080/15216540701545991     Document Type: Article

References (47)

1. Beal, M. F., and Shults, C. W. (2003) Effects of Coenzyme Q10 in Huntington's disease and early Parkinson's disease. Biofactors 18, 153-161.
2. Miller, R. W., and Curry, J. R. (1969) Mammalian dihydroorotate- ubiquinone reducatse complex. II. Correlation with cytochrome oxidase, mode of linkage with the cytochrome chain, and general properties. Can. J. Biochem. 47, 725-734.
3. Forsmark, P., et al. (1991) Inhibition of lipid peroxidation by ubiquinol in submitochondrial particles in the absence of vitamin E. FEBS Lett. 285, 39-43.
4. Takayanagi, R., Takeshige, K., and Minakami, S. (1980) NADH- and NADPH-dependent lipid peroxidation in bovine heart submitochondrial particles. Dependence on the rate of electron flow in the respiratory chain and an antioxidant role of ubiquinol. Biochem. J. 192, 853-860.
5. Kagan, V., Serbinova, E., and Packer, L. (1990) Antioxidant effects of ubiquinones in microsomes and mitochondria are mediated by tocopherol recycling. Biochem. Biophys. Res. Commun. 169, 851-857.
6. Mellors, A., and Tappel, A. L. (1966) The inhibition of mitochondrial peroxidation by ubiquinone and ubiquinol. J. Biol. Chem. 241, 4353-4356.
7. Stoyanovsky, D. A., Osipov, A. N., Quinn, P. J., and Kagan, V. E. (1995) Ubiquinone-dependent recycling of vitamin E radicals by superoxide. Arch. Biochem. Biophys. 323, 343-351.
8. Echtay, K. S., Winkler, E., Frischmuth, K., and Klingenberg, M. (2001) Uncoupling proteins 2 and 3 are highly active H(+) transporters and highly nucleotide sensitive when activated by coenzyme Q (ubiquinone). Proc. Natl. Acad. Sci. USA. 98, 1416-1421.
9. Esteves, T. C., Echtay, K. S., Jonassen, T., Clarke, C. F., and Brand, M. D. (2004) Ubiquinone is not required for proton conductance by uncoupling protein 1 in yeast mitochondria. Biochem. J. 379, 309-315.
10. Jaburek, M., and Garlid, K. D. (2003) Reconstitution of recombinant uncoupling proteins: UCP1, -2, and -3 have similar affinities for ATP and are unaffected by coenzyme Q10. J. Biol. Chem. 278, 25825-25831.
11. Littarru, G. P., and Tiano, L. (2005) Clinical aspects of coenzyme Q10: An update. Curr. Opin. Clin. Nutr. Metab. Care 8, 641-646.
12. Winkler-Stuck, K., Wiedemann, F. R., Wallesch, C. W., and Kunz, W. S. (2004) Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients. J. Neurol. Sci. 220, 41-48.
13. Shults, C. W., et al. (2002) Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59, 1541-1550.
14. Shults, C. W. (2005) Therapeutic role of coenzyme Q(10) in Parkinson's disease. Pharmacol. Ther. 107, 120-130.
15. Beal, M. F. (2004) Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J. Bioenerg. Biomembr. 36, 381-386.
16. Lalani, S. R., et al. (2005) Isolated mitochondrial myopathy associated with muscle coenzyme Q10 deficiency. Arch. Neurol. 62, 317-320.
17. Hart, P. E., et al. (2005) Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch. Neurol. 62, 621-626.
18. Feher, J., et al. (2005) Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10. Ophthalmologica 219, 154-166.
19. Sandor, P. S., et al. (2005) Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 64, 713-715.
20. Balercia, G., et al. (2002) Coenzyme Q10 levels in idiopathic and varicocele-associated asthenozoospermia. Andrologia 34, 107-111.
21. Balercia, G., et al. (2004) Coenzyme Q(10) supplementation in infertile men with idiopathic asthenozoospermia: an open, uncontrolled pilot study. Fertil. Steril. 81, 93-98.
22. Rosenfeldt, F., et al. (2005) Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue. J. Thorac. Cardiovasc. Surg. 129, 25-32.
23. Damian, M. S., et al. (2004) Coenzyme Q10 combined with mild hypothermia after cardiac arrest: a preliminary study. Circulation 110, 3011-3016.
24. Berman, M., et al. (2004) Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clin. Cardiol. 27, 295-299.
25. Doring, F., Schmitt, R., Bernhardt, W. M., Klapper, M., Bachmann, S., Daniel, H., and Groneberg, D. A. (2005) Hypothyroidism induces expression of the peptide transporter PEPT2. Biol. Chem. 386, 785-790.
26. Gorelick, C., Lopez-Jones, M., Goldberg, G. L., Romney, S. L., and Khabele, D. (2004) Coenzyme Q10 and lipid-related gene induction in HeLa cells. Am. J. Obstet. Gynecol. 190, 1432-1434.
27. Linnane, A. W., et al. (2002) Cellular redox activity of coenzyme Q10: effect of CoQ10 supplementation on human skeletal muscle. Free Radic. Res. 36, 445-453.
28. Scherf, M., Epple, A., and Werner, T. (2005) The next generation of literature analysis: integration of genomic analysis into text mining. Brief Bioinform. 6, 287-297.
29. Werner, T. (2001) Target gene identification from expression array data by promoter analysis. Biomol. Eng. 17, 87-94.
30. Klingenhoff, A., Frech, K., Quandt, K., and Werner, T. (1999) Functional promoter modules can be detected by formal models independent of overall nucleotide sequence similarity. Bioinformatics 15, 180-186.
31. Cartharius, K., et al. (2005) MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21, 2933-2942.
32. Tasheva, E. S., Klocke, B., and Conrad, G. W. (2004) Analysis of transcriptional regulation of the small leucine rich proteoglycans. Mol. Vis. 10, 758-772.
33. Berman, B. P., et al. (2002) Exploiting transcription factor binding site clustering to identify cis-regulatory modules involved in pattern formation in the Drosophila genome. Proc. Natl. Acad. Sci. USA. 99, 757-762.
34. Tergaonkar, V. (2006) NFkappaB pathway: a good signaling paradigm and therapeutic target. Int. J. Biochem. Cell Biol. 38, 1647-1653.
35. Andres, V., Nadal-Ginard, B., and Mahdavi, V. (1992) Clox, a mammalian homeobox gene related to Drosophila cut, encodes DNA-binding regulatory proteins differentially expressed during development. Development 116, 321-334.
36. Hirai, H. (1999) The transcription factor Evi-1. Int. J. Biochem. Cell Biol. 31, 1367-1371.
37. Lemons, D., and McGinnis, W. (2006) Genomic evolution of Hox gene clusters. Science 313, 1918-1922.
38. Venarske, D., and deShazo, R. D. (2003) Molecular mechanisms of allergic disease. South Med. J. 96, 1049-1054.
39. Yaron, G., et al. (2006) C-reactive protein promotes platelet adhesion to endothelial cells: a potential pathway in atherothrombosis. Br. J. Haematol. 134, 426-431.
40. Seiffert, D., Ciambrone, G., Wagner, N. V., Binder, B. R., and Loskutoff, D. J. (1994) The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J. Biol. Chem. 269, 2659-2666.
41. Ekmekci, H., et al. (2002) Plasma vitronectin levels in patients with coronary atherosclerosis are increased and correlate with extent of disease. J. Thromb. Thrombolysis 14, 221-225.
42. Scatena, M., et al. (1998) NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J. Cell Biol. 141, 1083-1093.
43. Murphy, J. F., et al. (1994) The vitronectin receptor (alpha v beta 3) is implicated, in cooperation with P-selectin and platelet-activating factor, in the adhesion of monocytes to activated endothelial cells. Biochem. J. 304 (Pt 2), 537-542.
44. Serebruany, V. L., et al. (1996) Hemostatic changes after dietary coenzyme Q10 supplementation in swine. J. Cardiovasc. Pharmacol. 28, 175-181.
45. Serebruany, V. L., et al. (1997) Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression. J. Cardiovasc. Pharmacol. 29, 16-22.
46. Watts, G. F., et al. (2002) Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia 45, 420-426.
47. Belardinelli, R., et al. (2006) Coenzyme Q10 and exercise training in chronic heart failure. Eur. Heart J. 27, 2675-2681.